Korea Research Institute of Bioscience and Biotechnology

Industry-academic Cooperation Foundation, the Catholic University of Korea

Sun Jung Cho

Jong-Ho Lee

Young Woo Park

Jung Jae Yu

Ji Hyun Park

Mi Kyung Park

Ho Youn Kim

Mi La Cho

Ki Won Jo

Min Ji Seo

Jun Geol Ryu

Jae Kyeong Byun

Hye Jwa Oh

Srok Ho Yoo

Jin Sil Park

Sun-Ha Yoon

Yun Ju Woo

Eun Jung Song

The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (&#x3b1;) and IL-21. The composition containing the double antagonist to TNF-&#x3b1; and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.

Dual antagonist for TNF-&#x3b1; and IL-21 for preventing and treating autoimmune diseases

Growing community of inventors

Suwon-si, South Korea

Sun Jung Cho